[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Autolus Therapeutics Plc ADR (AUTL)

Autolus Therapeutics Plc ADR (AUTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 412,522
  • Shares Outstanding, K 266,143
  • Annual Sales, $ 75,390 K
  • Annual Income, $ -287,530 K
  • EBIT $ -271 M
  • EBITDA $ -261 M
  • 60-Month Beta 2.04
  • Price/Sales 5.58
  • Price/Cash Flow N/A
  • Price/Book 2.36

Options Overview Details

View History
  • Implied Volatility 251.87% (+3.20%)
  • Historical Volatility 62.90%
  • IV Percentile 49%
  • IV Rank 28.72%
  • IV High 697.19% on 11/10/25
  • IV Low 72.43% on 05/20/25
  • Expected Move (DTE 23) 0.0425 (2.66%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 22
  • Volume Avg (30-Day) 619
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 13,029
  • Open Int (30-Day) 11,329
  • Expected Range 1.5575 to 1.6425

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.29
  • Number of Estimates 3
  • High Estimate $-0.28
  • Low Estimate $-0.30
  • Prior Year $-0.26
  • Growth Rate Est. (year over year) -11.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1750 +36.17%
on 03/27/26
1.6850 -5.04%
on 04/17/26
+0.2300 (+16.79%)
since 03/20/26
3-Month
1.1750 +36.17%
on 03/27/26
1.9300 -17.10%
on 02/25/26
+0.0800 (+5.26%)
since 01/22/26
52-Week
1.1500 +39.13%
on 05/07/25
2.7000 -40.74%
on 07/24/25
unch (unch)
since 04/22/25

Most Recent Stories

More News
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON and GAITHERSBURG, Md., April 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.6000 (+3.23%)
Autolus Therapeutics to Participate in Upcoming Investor Conferences

LONDON and GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.6000 (+3.23%)
Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates 

AUCATZYL ® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025 AUCATZYL ® UK launch underway following successful...

AUTL : 1.6000 (+3.23%)
Autolus Therapeutics Faces Widening Losses as Analysts Slash Expectations Ahead of Earnings

Barchart Research What to Expect from AUTL Earnings AUTL Generated March 26, 2026 Current Price $1.2900 EPS Estimate $-0.31 Consensus Rating Strong Buy Average Move 9.00% Autolus Therapeutics Faces Widening...

AUTL : 1.6000 (+3.23%)
Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026

LONDON and GAITHERSBURG, Md., March 16, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.6000 (+3.23%)
Autolus Therapeutics to Participate in Upcoming Investor Conferences

LONDON and GAITHERSBURG, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.6000 (+3.23%)
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON and GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.6000 (+3.23%)
Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026

Company expects preliminary unaudited AUCATZYL® net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025 Autolus anticipates...

AUTL : 1.6000 (+3.23%)
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform

Autolus will evaluate Cellares’ fully automated, high-throughput manufacturing platform in preparation for expansion into new indications

AUTL : 1.6000 (+3.23%)
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform

SOUTH SAN FRANCISCO, Calif. and LONDON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering...

AUTL : 1.6000 (+3.23%)

Business Summary

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London,...

See More

Key Turning Points

3rd Resistance Point 1.6933
2nd Resistance Point 1.6467
1st Resistance Point 1.6233
Last Price 1.6000
1st Support Level 1.5533
2nd Support Level 1.5067
3rd Support Level 1.4833

See More

52-Week High 2.7000
Fibonacci 61.8% 2.1079
Fibonacci 50% 1.9250
Fibonacci 38.2% 1.7421
Last Price 1.6000
52-Week Low 1.1500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.